[Innovative Personalized Medicine for Immunosuppressive Drugs Based on Novel Control Theory of Pharmacokinetics]

Yakugaku Zasshi. 2024;144(12):1075-1080. doi: 10.1248/yakushi.24-00140.
[Article in Japanese]

Abstract

Tacrolimus is widely recognized as an anti-rejection agent due to its immunosuppressive characteristics. It binds to the immunophilin FK506-binding protein (FKBP) and thus to calcineurin, and inhibits its activity. Tacrolimus' therapeutic concentration range in blood is narrow, and its pharmacokinetics are highly variable among individuals. First, because tacrolimus primarily distributes to red blood cells (RBCs), anemia and blood transfusions can cause fluctuations in tacrolimus blood concentrations. Variations in blood tacrolimus concentration significantly correlated with variations in RBC count, hemoglobin level, and hematocrit value, but not with variations in white blood cell or platelet counts. Interestingly, FKBP played an important role in tacrolimus distribution to RBCs. The effects of intracellular and extracellular FKBP levels on RBC distribution of tacrolimus in circulating blood were substantial. Secondly, proteins affecting pharmacokinetics can differ at the genetic level in their expression and functional potency. Genetic polymorphisms that influence tacrolimus pharmacokinetics have been reported. A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 (CYP) 3A5 is a particularly influential factor affecting tacrolimus pharmacokinetics in Japanese patients. CYP3A5 polymorphisms correlated with individual differences in tacrolimus blood concentration changes after starting continuous infusion in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. In addition, CYP3A5*3 polymorphism also correlated with differences in the frequency of acute graft-versus-host disease (GVHD) development in allogeneic HSCT recipients.

Keywords: FK506-binding protein; cytochrome P450 3A5; hematopoietic stem cell transplantation; red blood cell; tacrolimus.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Cytochrome P-450 CYP3A* / genetics
  • Cytochrome P-450 CYP3A* / metabolism
  • Erythrocytes / metabolism
  • Graft vs Host Disease / etiology
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunosuppressive Agents* / pharmacokinetics
  • Polymorphism, Genetic*
  • Precision Medicine*
  • Tacrolimus Binding Proteins / genetics
  • Tacrolimus* / pharmacokinetics

Substances

  • Tacrolimus
  • Immunosuppressive Agents
  • Cytochrome P-450 CYP3A
  • CYP3A5 protein, human
  • Tacrolimus Binding Proteins